How Earnings Beat, Legal Resolution and New Mississippi Hospital Will Impact Encompass Health (EHC) Investors

How Earnings Beat, Legal Resolution and New Mississippi Hospital Will Impact Encompass Health (EHC) Investors

Simply Wall St

Tue, February 17, 2026 at 5:08 AM GMT+9 3 min read

In this article:

EHC

-1.71%

Encompass Health recently reported strong fourth-quarter and full-year 2025 results, issued 2026 revenue guidance of US$6.37 billion–US$6.47 billion, resolved legacy legal claims, expanded its board, and announced plans for a new 50‑bed inpatient rehabilitation hospital in Flowood, Mississippi opening in 2027.
Together, the earnings beat, disciplined labor cost control, Mississippi capacity expansion, and recovery of legal damages highlight management’s focus on growth, efficiency, and strengthening the inpatient rehabilitation platform.
We’ll now examine how this combination of stronger earnings, new capacity in Mississippi, and legal resolution affects Encompass Health’s investment narrative.

Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

Encompass Health Investment Narrative Recap

To own Encompass Health, you need to believe inpatient rehabilitation will remain central to complex post‑acute care and that the company can manage staffing, capital spending and reimbursement exposure. The latest earnings beat and 2026 revenue guidance reinforce the near term earnings trajectory, while the Flowood hospital plan and legal recovery do not materially change the key near term catalyst, which is continued margin support from tighter labor cost control, or the main risk, which is still heavy reliance on government reimbursement.

The most relevant recent development is the collection of US$43.1 million in legal damages and the profit‑sharing interest in VitalCaring Group. This cash recovery slightly offsets the burden of funding de novo hospitals such as Flowood and may help cushion the financial impact if new facilities ramp more slowly or cost more than expected, but it does not remove the underlying execution and capital allocation risks around Encompass Health’s build‑out program.

But investors should also be aware that if reimbursement rules or audit practices shift more aggressively than expected, then…

Read the full narrative on Encompass Health (it’s free!)

Encompass Health’s narrative projects $7.2 billion revenue and $711.6 million earnings by 2028. This requires 8.1% yearly revenue growth and a $189.2 million earnings increase from $522.4 million today.

Uncover how Encompass Health’s forecasts yield a $142.73 fair value, a 30% upside to its current price.

Exploring Other Perspectives

EHC 1-Year Stock Price Chart

Four members of the Simply Wall St Community currently see Encompass Health’s fair value between US$99.17 and US$142.87, underlining how far opinions can diverge. When you weigh those views against the company’s dependence on Medicare and other government payers, it becomes even more important to explore several different scenarios for future earnings resilience.

Story Continues  

Explore 4 other fair value estimates on Encompass Health - why the stock might be worth 10% less than the current price!

Build Your Own Encompass Health Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

A great starting point for your Encompass Health research is our analysis highlighting 5 key rewards and 2 important warning signs that could impact your investment decision.
Our free Encompass Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Encompass Health's overall financial health at a glance.

Seeking Other Investments?

Our top stock finds are flying under the radar-for now. Get in early:

AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.

_ This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._

Companies discussed in this article include EHC.

Have feedback on this article? Concerned about the content? Get in touch with us directly._ Alternatively, email editorial-team@simplywallst.com_

Terms and Privacy Policy

Privacy Dashboard

More Info

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments